Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.

Novartis' late-stage pelacarsen trial failed to significantly reduce cardiovascular events despite lowering Lp(a), eliminating a drug once projected to generate $4 billion-$5 billion in peak annual sales. Amgen shares fell 10% following the result, while Eli Lilly declined only about 3%, reflecting differences in Lilly's lepodisiran approach and its broader late-stage patient population. Lilly's $23 billion of Q2 2026 revenue, including $14.9 billion from Mounjaro and Zepbound, limits the potential financial impact of an Lp(a) pipeline setback.

Analysis

The key repricing is not a single-asset NPV loss but a higher discount rate on Lp(a) as a cardiovascular target. Until event curves, achieved time-averaged Lp(a) lowering, baseline risk, and discontinuation rates are disclosed, the result cannot distinguish target failure from inadequate exposure or trial design. That distinction matters because AMGN's olpasiran and LLY's lepodisiran use RNAi rather than ASO delivery, but superior biomarker suppression alone will not command prior peak-sales assumptions if outcomes require near-complete, lifelong suppression or a narrower genetically defined population.

AMGN has the most direct near-term valuation sensitivity: its Lp(a) program is a meaningful source of post-2028 pipeline optionality relative to LLY, whose obesity franchise dominates earnings and absorbs a cardiovascular pipeline de-rating. IONS faces a less obvious negative read-through: the setback raises investor scrutiny of whether ASO-mediated biomarker changes translate into hard outcomes, potentially increasing required returns across its partnered cardiometabolic platform. NVS's selloff should be contained by portfolio diversification unless disclosure points to an avoidable execution issue that damages its development credibility beyond this asset.

The next tradable catalyst is the full dataset at the medical congress, likely days to weeks rather than quarters. A clean exposure-response relationship or favorable subgroup would support a modality-specific explanation and relieve AMGN/LLY; uniformly neutral event curves despite substantial sustained Lp(a) reduction would justify further multiple compression for the entire class over 1-3 months. Over 6-18 months, the commercial opportunity may migrate from a broad prevention population to high-risk secondary-prevention patients, reducing addressable revenue but improving payer willingness to reimburse demonstrable responders.

Key Decisions for Investors

• Maintain LLY as the preferred large-cap exposure versus AMGN through the data release: pair long LLY / short AMGN in equal dollar size for 1-3 months. The thesis is relative pipeline-duration risk, not a new LLY upside catalyst; exit if full data show a clear ASO-specific exposure or adherence failure, which would disproportionately repair AMGN's class probability.
• Do not add directional AMGN until the full pelacarsen dataset identifies achieved lowering and event-curve timing. Set an alert for a further 8-12% decline from the post-result level; at that point, consider a tactical long only if evidence supports a modality/trial-design explanation, with a stop on evidence of neutral outcomes at deep sustained Lp(a) suppression.
• Reduce any IONS exposure tied to platform-level cardiovascular optionality ahead of the congress. Re-enter only after management quantifies royalty/partner economics and clarifies whether other ASO programs rely on the same biomarker-to-outcome premise; the falsifier is evidence that pelacarsen failed for target biology rather than drug-specific exposure.
• Treat NVS weakness as a valuation watch rather than an automatic long. A 6-12 month entry is attractive only if management offsets lost pipeline value through guidance, buybacks, or credible late-stage replacements; absent that, the market may continue to apply a higher probability of pipeline attrition after multiple recent setbacks.